---
title: Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy
date: '2023-09-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37768671/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230928180748&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS AND RELEVANCE: In patients with ATTRv polyneuropathy, the
  eplontersen treatment group demonstrated changes consistent with significantly lowered
  serum transthyretin concentration, less neuropathy impairment, and better quality
  of life compared with a historical ...'
disable_comments: true
---
CONCLUSIONS AND RELEVANCE: In patients with ATTRv polyneuropathy, the eplontersen treatment group demonstrated changes consistent with significantly lowered serum transthyretin concentration, less neuropathy impairment, and better quality of life compared with a historical ...